Business Wire

MORINAGA-MILK-INDUSTRY

31.8.2021 19:54:06 CEST | Business Wire | Press release

Share
Morinaga Milk Reveals Major Breakthroughs in a ‘Bifidobacteria Training’ Program With Professional Footballer Yuto Nagatomo

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a pioneer in bifidobacteria and gut microbiota research, reveals that its collaborative ‘Bifidobacteria Training’ project (launched in June 2020) helped professional athlete Yuto Nagatomo improve his gut microbiota. Nagatomo stayed on the program for a full year, and has been outspoken about the changes in his gut microbiota that not only improved his digestive system, but also his physical condition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005058/en/

About the ‘Bifidobacteria Training’ program

The program encourages participants to incorporate bifidobacteria into their existing knowledge, diet, and physical and mental health regimens with the aim of improving the environment of the large intestine through input from inside and outside the body.

The ‘Bifidobacteria Training’ program website offers a wealth of information not available elsewhere, including varied content on knowledge, diet, exercise, and mental health, and a profile of Yuto Nagatomo’s gut microbiota shaped by his consistent intake of bifidobacteria since 2020.

1. Overview of Report on ‘Bifidobacteria Training’ CROSS-TALK 2020-2021

Footballer Yuto Nagatomo started taking bifidobacteria in July 2020, during the offseason. He later signed with a French (Ligue 1) team, and his condition suffered as he attempted to adapt to an unfamiliar living environment. However, his digestive system steadily regained its balance thanks to his persistence with the ‘Bifidobacteria Training’ program. Our analysis of his gut microbiota revealed inconsistency immediately after his move to France, followed by certain changes that suggested a strong connection between his enteric bacteria and his physical condition.

Nagatomo recognized the changes as they were occurring. “My condition improved because I stayed with the ‘Bifidobacteria Training’ program every day,” he said. “Even on days I couldn’t sleep, both my digestive system and my physical condition were stable.” He also noted that his recovery speed had improved, and identified the source without uncertainty. “[Bifidobacteria] saved me.” His condition and performance on the field continuously improved. “I’m so much more confident now that I have the final piece of the puzzle in my goal to represent Japan in the 2022 World Cup.”

He reflected on his full year on the ‘Bifidobacteria Training’ program, noting that staying with it was important, yet not all that burdensome. “[Staying with the program] was everything for my gut microbiota,” he said in a nod to a Japanese adage about the value of persistence in sport. “It helped me so much. I’m grateful for the support.”

2. Changes in Yuto Nagatomo’s gut microbiota on the ‘Bifidobacteria Training’ program

Dr. Toshitaka Odamaki, Manager of the Microbiota Research Department at the Next Generation Science Institute of Morinaga Milk, analyzed Nagatomo’s gut microbiota over the roughly seven months in which he took bifidobacteria. “The balance of enteric bacteria shifted substantially after [Nagatomo] moved from Japan to France, but his intake of bifidobacteria and balanced meals created a new balance that stabilized in December,” Dr. Odamaki said, also confirming the disappearance of the harmful bacteria may be associated with the cause of Nagatomo’s illnesses. “The analysis showed increases in good bacteria such as bifidobacteria and butyrate-producing bacteria following his persistence with the ‘Bifidobacteria Training’ program.” Dr. Odamaki also noted that Nagatomo had a growing population of bacteria that is linked to the performance of professional athletes.” The changes in gut microbiota could be a factor behind Nagatomo’s sense that his condition improved.”

“This is the first experience to track the detailed changes in an individual’s gut microbial composition,” Dr. Odamaki said. “Our analysis illustrated a strong connection between tangible feelings and enteric bacteria, which are normally hidden from us, a significant finding among Morinaga Milk’s research.”

About professional footballer Yuto Nagatomo

Born in Ehime Prefecture, Japan in 1986. Made his official J. League debut with FC Tokyo in 2008. Invited to play on the Japanese national team for the first time in May 2008, and appeared in the Beijing Olympics in August of that year. Played every minute of Japan’s four games in the 2010 World Cup in South Africa, signed with Cesena of Serie A (Italy) in July of that year. Signed with the vaunted Inter Milan in January 2011. Played every minute of Japan’s games in the 2014 World Cup in Brazil. Joined Galatasaray S.K. of the TFF 1. Lig (Turkey) on loan in 2018. Advanced to the finals for the first time at the 2018 World Cup in Russia. Joined Galatasaray S.K. on a permanent deal in 2019, and won two consecutive Süper Lig titles and two Turkish Cup trophies. Signed with Olympique de Marseilles of Ligue 1 (France) on August 31, 2020. Developed original exercise methods incorporating elements of stretching, yoga, and core training, worked with a personal chef and physician to develop a fat-adaptation diet, and more. With a style of examining his body from the inside and outside, he continues to maintain a high level of athletic performance, and has declared his goal to represent Japan in the 2022 World Cup.

About Morinaga Milk’s initiatives with Yuto Nagatomo

Morinaga Milk sensed Yuto Nagatomo’s dedication to constant improvement as a professional athlete, evident in his commitment to physical fitness, diet, and other facets of health within his control. We heard of his concern about his digestive system suffering during extended stays outside Japan despite unflagging self-control, and wanted to apply our findings from many years of research to try to improve his intestinal environment and help him continue to evolve as an athlete from the inside out.

Additionally, “nurturing the next generation” is one of the themes of ESG-focused management, a basic policy from our Medium-Term Business Plan. We aim to teach people the importance of food for maintaining healthy bodies and minds, while also helping them grow as people with positive attributes like agency, autonomy, and motivation to take on challenges, all in an effort to nurture the next generation in order to create a sustainable society.

These goals resonate with Nagatomo, who for his part has established the Yuto Nagatomo Football Academy (YNFA), founded Cuore Inc. with the aim of using his influence as an athlete to solve health problems around the world, and devoted energy to activities in support of single-parent families.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release

Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release

Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release

The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release

Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye